So now, you know, we have competing standards of care in the frontline for AML, which is either high intensity induction or ...
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden ...
The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) ...
Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...
Acute leukemia is a group of hematologic malignancies categorized according to the immature cells that proliferate and replace the normal bone marrow. Flow cytometry has emerged as a cornerstone in ...
The CytoCell KMT2A Breakapart FISH Probe Kit PDx is approved as a companion diagnostic for revumenib in KMT2A translocated acute leukemia. Revumenib showed a 21.2% complete remission rate in ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
“My first thought was, ‘I’m going to die,‘ ” she recalled of receiving her actual diagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results